Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 237

1.

Corrigendum to: Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency.

Taylor WRJ, Kheng S, Muth S, Tor P, Kim S, Bjorge S, Topps N, Kosal K, Sothea K, Souy P, Char CM, Vanna C, Ly P, Khieu V, Christophel E, Kerleguer A, Pantaleo A, Mukaka M, Menard D, Baird JK.

J Infect Dis. 2019 Nov 26. pii: jiz530. doi: 10.1093/infdis/jiz530. [Epub ahead of print] No abstract available.

PMID:
31770431
2.

Efficacy of directly-observed chloroquine-primaquine treatment for uncomplicated acute Plasmodium vivax malaria in northeast Myanmar: A prospective open-label efficacy trial.

Xu S, Zeng W, Ngassa Mbenda HG, Liu H, Chen X, Xiang Z, Li C, Zhang Y, Baird JK, Yang Z, Cui L.

Travel Med Infect Dis. 2019 Oct 8:101499. doi: 10.1016/j.tmaid.2019.101499. [Epub ahead of print]

PMID:
31604130
3.

The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis.

Commons RJ, Simpson JA, Thriemer K, Abreha T, Adam I, Anstey NM, Assefa A, Awab GR, Baird JK, Barber BE, Chu CS, Dahal P, Daher A, Davis TME, Dondorp AM, Grigg MJ, Humphreys GS, Hwang J, Karunajeewa H, Laman M, Lidia K, Moore BR, Mueller I, Nosten F, Pasaribu AP, Pereira DB, Phyo AP, Poespoprodjo JR, Sibley CH, Stepniewska K, Sutanto I, Thwaites G, Hien TT, White NJ, William T, Woodrow CJ, Guerin PJ, Price RN.

PLoS Med. 2019 Oct 4;16(10):e1002928. doi: 10.1371/journal.pmed.1002928. eCollection 2019 Oct.

4.

Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency.

Taylor WRJ, Kheng S, Muth S, Tor P, Kim S, Bjorge S, Topps N, Kosal K, Sothea K, Souy P, Char CM, Vanna C, Ly P, Khieu V, Christophel E, Kerleguer A, Pantaleo A, Mukaka M, Menard D, Baird JK.

J Infect Dis. 2019 Oct 22;220(11):1750-1760. doi: 10.1093/infdis/jiz313.

5.

Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.

He X, Pan M, Zeng W, Zou C, Pi L, Qin Y, Zhao L, Qin P, Lu Y, Baird JK, Huang Y, Cui L, Yang Z.

BMC Infect Dis. 2019 Aug 9;19(1):704. doi: 10.1186/s12879-019-4357-9.

6.

8-Aminoquinoline Therapy for Latent Malaria.

Baird JK.

Clin Microbiol Rev. 2019 Jul 31;32(4). pii: e00011-19. doi: 10.1128/CMR.00011-19. Print 2019 Sep 18. Review.

PMID:
31366609
7.

The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.

Commons RJ, Simpson JA, Thriemer K, Chu CS, Douglas NM, Abreha T, Alemu SG, Añez A, Anstey NM, Aseffa A, Assefa A, Awab GR, Baird JK, Barber BE, Borghini-Fuhrer I, D'Alessandro U, Dahal P, Daher A, de Vries PJ, Erhart A, Gomes MSM, Grigg MJ, Hwang J, Kager PA, Ketema T, Khan WA, Lacerda MVG, Leslie T, Ley B, Lidia K, Monteiro WM, Pereira DB, Phan GT, Phyo AP, Rowland M, Saravu K, Sibley CH, Siqueira AM, Stepniewska K, Taylor WRJ, Thwaites G, Tran BQ, Hien TT, Vieira JLF, Wangchuk S, Watson J, William T, Woodrow CJ, Nosten F, Guerin PJ, White NJ, Price RN.

BMC Med. 2019 Aug 1;17(1):151. doi: 10.1186/s12916-019-1386-6.

8.

Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial.

Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Assawariyathipat T, Assefa A, Auburn S, Chand K, Chau NH, Cheah PY, Dong LT, Dhorda M, Degaga TS, Devine A, Ekawati LL, Fahmi F, Hailu A, Hasanzai MA, Hien TT, Khu H, Ley B, Lubell Y, Marfurt J, Mohammad H, Moore KA, Naddim MN, Pasaribu AP, Pasaribu S, Promnarate C, Rahim AG, Sirithiranont P, Solomon H, Sudoyo H, Sutanto I, Thanh NV, Tuyet-Trinh NT, Waithira N, Woyessa A, Yamin FY, Dondorp A, Simpson JA, Baird JK, White NJ, Day NP, Price RN.

Lancet. 2019 Sep 14;394(10202):929-938. doi: 10.1016/S0140-6736(19)31285-1. Epub 2019 Jul 18.

9.

Phase Rule and the Universality of Critical Phenomena in Chemically Reacting Liquid Mixtures.

Baird JK, Lang JR, Wang X, Mukherjee A, Norris P.

J Phys Chem B. 2019 Jul 5;123(26):5545-5554. doi: 10.1021/acs.jpcb.9b02978. Epub 2019 Jun 19.

PMID:
31244101
10.

Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000-17: a spatial and temporal modelling study.

Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, Pfeffer DA, Cameron E, Rao PC, Casey D, Gibson HS, Rozier JA, Dalrymple U, Keddie SH, Collins EL, Harris JR, Guerra CA, Thorn MP, Bisanzio D, Fullman N, Huynh CK, Kulikoff X, Kutz MJ, Lopez AD, Mokdad AH, Naghavi M, Nguyen G, Shackelford KA, Vos T, Wang H, Lim SS, Murray CJL, Price RN, Baird JK, Smith DL, Bhatt S, Weiss DJ, Hay SI, Gething PW.

Lancet. 2019 Jul 27;394(10195):332-343. doi: 10.1016/S0140-6736(19)31096-7. Epub 2019 Jun 19.

11.

"Lively" invasive Plasmodium vivax causes severe and complicated malaria.

Baird JK.

Travel Med Infect Dis. 2019 Jul - Aug;30:7-8. doi: 10.1016/j.tmaid.2019.06.004. Epub 2019 Jun 14. No abstract available.

PMID:
31202701
12.

Essential guidance on malaria elimination in its history.

Baird JK.

J Vector Borne Dis. 2019 Jan-Mar;56(1):11-14. doi: 10.4103/0972-9062.257768. Review. No abstract available.

13.

Growing evidence of Plasmodium vivax across malaria-endemic Africa.

Twohig KA, Pfeffer DA, Baird JK, Price RN, Zimmerman PA, Hay SI, Gething PW, Battle KE, Howes RE.

PLoS Negl Trop Dis. 2019 Jan 31;13(1):e0007140. doi: 10.1371/journal.pntd.0007140. eCollection 2019 Jan. Erratum in: PLoS Negl Trop Dis. 2019 Jun 28;13(6):e0007525.

14.

Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.

Baird JK, Louisa M, Noviyanti R, Ekawati L, Elyazar I, Subekti D, Chand K, Gayatri A, Instiaty, Soebianto S, Crenna-Darusallam C, Djoko D, Hasto BD, Meriyenes D, Wesche D, Nelwan EJ, Sutanto I, Sudoyo H, Setiabudy R.

JAMA Netw Open. 2018 Aug 3;1(4):e181449. doi: 10.1001/jamanetworkopen.2018.1449.

15.

The key role of T cells in Parkinson's disease pathogenesis and therapy.

Baird JK, Bourdette D, Meshul CK, Quinn JF.

Parkinsonism Relat Disord. 2019 Mar;60:25-31. doi: 10.1016/j.parkreldis.2018.10.029. Epub 2018 Oct 28. Review.

PMID:
30404763
16.

Tafenoquine for travelers' malaria: evidence, rationale and recommendations.

Baird JK.

J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay110.

17.

The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis.

Commons RJ, Simpson JA, Thriemer K, Humphreys GS, Abreha T, Alemu SG, Añez A, Anstey NM, Awab GR, Baird JK, Barber BE, Borghini-Fuhrer I, Chu CS, D'Alessandro U, Dahal P, Daher A, de Vries PJ, Erhart A, Gomes MSM, Gonzalez-Ceron L, Grigg MJ, Heidari A, Hwang J, Kager PA, Ketema T, Khan WA, Lacerda MVG, Leslie T, Ley B, Lidia K, Monteiro WM, Nosten F, Pereira DB, Phan GT, Phyo AP, Rowland M, Saravu K, Sibley CH, Siqueira AM, Stepniewska K, Sutanto I, Taylor WRJ, Thwaites G, Tran BQ, Tran HT, Valecha N, Vieira JLF, Wangchuk S, William T, Woodrow CJ, Zuluaga-Idarraga L, Guerin PJ, White NJ, Price RN.

Lancet Infect Dis. 2018 Sep;18(9):1025-1034. doi: 10.1016/S1473-3099(18)30348-7. Epub 2018 Jul 20.

18.

Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group.

Thriemer K, Bobogare A, Ley B, Gudo CS, Alam MS, Anstey NM, Ashley E, Baird JK, Gryseels C, Jambert E, Lacerda M, Laihad F, Marfurt J, Pasaribu AP, Poespoprodjo JR, Sutanto I, Taylor WR, van den Boogaard C, Battle KE, Dysoley L, Ghimire P, Hawley B, Hwang J, Khan WA, Mudin RNB, Sumiwi ME, Ahmed R, Aktaruzzaman MM, Awasthi KR, Bardaji A, Bell D, Boaz L, Burdam FH, Chandramohan D, Cheng Q, Chindawongsa K, Culpepper J, Das S, Deray R, Desai M, Domingo G, Duoquan W, Duparc S, Floranita R, Gerth-Guyette E, Howes RE, Hugo C, Jagoe G, Sariwati E, Jhora ST, Jinwei W, Karunajeewa H, Kenangalem E, Lal BK, Landuwulang C, Le Perru E, Lee SE, Makita LS, McCarthy J, Mekuria A, Mishra N, Naket E, Nambanya S, Nausien J, Duc TN, Thi TN, Noviyanti R, Pfeffer D, Qi G, Rahmalia A, Rogerson S, Samad I, Sattabongkot J, Satyagraha A, Shanks D, Sharma SN, Sibley CH, Sungkar A, Syafruddin D, Talukdar A, Tarning J, Ter Kuile F, Thapa S, Theodora M, Huy TT, Waramin E, Waramori G, Woyessa A, Wongsrichanalai C, Xa NX, Yeom JS, Hermawan L, Devine A, Nowak S, Jaya I, Supargiyono S, Grietens KP, Price RN.

Malar J. 2018 Jun 20;17(1):241. doi: 10.1186/s12936-018-2380-8.

19.

Malaria Elimination: Time to Target All Species.

Lover AA, Baird JK, Gosling R, Price RN.

Am J Trop Med Hyg. 2018 Jul;99(1):17-23. doi: 10.4269/ajtmh.17-0869. Epub 2018 May 10. Review.

20.

Negligible Impact of Mass Screening and Treatment on Mesoendemic Malaria Transmission at West Timor in Eastern Indonesia: A Cluster-Randomized Trial.

Sutanto I, Kosasih A, Elyazar IRF, Simanjuntak DR, Larasati TA, Dahlan MS, Wahid I, Mueller I, Koepfli C, Kusriastuti R, Surya A, Laihad FJ, Hawley WA, Collins FH, Baird JK, Lobo NF.

Clin Infect Dis. 2018 Oct 15;67(9):1364-1372. doi: 10.1093/cid/ciy231.

21.

Anomalous Solubility of an Inert Solid in a Binary Liquid Mixture with a Critical Point of Solution.

Baird JK, Lang JR, Wang X, Huang S, Mukherjee A.

J Phys Chem B. 2018 Mar 22;122(11):2949-2956. doi: 10.1021/acs.jpcb.7b11058. Epub 2018 Mar 5.

PMID:
29461060
22.
23.

Theory of First Order Chemical Kinetics at the Critical Point of Solution.

Baird JK, Lang JR.

J Phys Chem A. 2017 Oct 26;121(42):8048-8052. doi: 10.1021/acs.jpca.7b07635. Epub 2017 Oct 13.

PMID:
28953393
24.

Management of Plasmodium vivax risk and illness in travelers.

Baird JK.

Trop Dis Travel Med Vaccines. 2017 Mar 28;3:7. doi: 10.1186/s40794-017-0049-x. eCollection 2017.

25.

Rational malaria chemoprophylaxis - The position of primaquine.

Baird JK.

Travel Med Infect Dis. 2017 May - Jun;17:3-4. doi: 10.1016/j.tmaid.2017.04.006. Epub 2017 Apr 24. No abstract available.

26.

Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group.

Thriemer K, Ley B, Bobogare A, Dysoley L, Alam MS, Pasaribu AP, Sattabongkot J, Jambert E, Domingo GJ, Commons R, Auburn S, Marfurt J, Devine A, Aktaruzzaman MM, Sohel N, Namgay R, Drukpa T, Sharma SN, Sarawati E, Samad I, Theodora M, Nambanya S, Ounekham S, Mudin RN, Da Thakur G, Makita LS, Deray R, Lee SE, Boaz L, Danansuriya MN, Mudiyanselage SD, Chinanonwait N, Kitchakarn S, Nausien J, Naket E, Duc TN, Do Manh H, Hong YS, Cheng Q, Richards JS, Kusriastuti R, Satyagraha A, Noviyanti R, Ding XC, Khan WA, Swe Phru C, Guoding Z, Qi G, Kaneko A, Miotto O, Nguitragool W, Roobsoong W, Battle K, Howes RE, Roca-Feltrer A, Duparc S, Bhowmick IP, Kenangalem E, Bibit JA, Barry A, Sintasath D, Abeyasinghe R, Sibley CH, McCarthy J, von Seidlein L, Baird JK, Price RN.

Malar J. 2017 Apr 5;16(1):141. doi: 10.1186/s12936-017-1784-1. Review.

27.

Defining the next generation of Plasmodium vivax diagnostic tests for control and elimination: Target product profiles.

Ding XC, Ade MP, Baird JK, Cheng Q, Cunningham J, Dhorda M, Drakeley C, Felger I, Gamboa D, Harbers M, Herrera S, Lucchi N, Mayor A, Mueller I, Sattabongkot J, Ratsimbason A, Richards J, Tanner M, González IJ.

PLoS Negl Trop Dis. 2017 Apr 3;11(4):e0005516. doi: 10.1371/journal.pntd.0005516. eCollection 2017 Apr.

28.

Telling the human story of Asia's invisible malaria burden.

Baird JK.

Lancet. 2017 Feb 25;389(10071):781-782. doi: 10.1016/S0140-6736(17)30556-1. No abstract available.

PMID:
28248161
29.

Asia-Pacific malaria is singular, pervasive, diverse and invisible.

Baird JK.

Int J Parasitol. 2017 Jun;47(7):371-377. doi: 10.1016/j.ijpara.2016.06.006. Epub 2016 Nov 9.

30.

Diagnosis and Treatment of Plasmodium vivax Malaria.

Baird JK, Valecha N, Duparc S, White NJ, Price RN.

Am J Trop Med Hyg. 2016 Dec 28;95(6 Suppl):35-51. doi: 10.4269/ajtmh.16-0171. Epub 2016 Oct 5.

31.

Attacking Plasmodium vivax.

Baird JK.

Am J Trop Med Hyg. 2016 Dec 28;95(6 Suppl):1-3. doi: 10.4269/ajtmh.16-0517. Epub 2016 Oct 5.

32.

Epidemiology of Plasmodium vivax in Indonesia.

Surjadjaja C, Surya A, Baird JK.

Am J Trop Med Hyg. 2016 Dec 28;95(6 Suppl):121-132. doi: 10.4269/ajtmh.16-0093. Epub 2016 Oct 5.

33.

Key Knowledge Gaps for Plasmodium vivax Control and Elimination.

Bassat Q, Velarde M, Mueller I, Lin J, Leslie T, Wongsrichanalai C, Baird JK.

Am J Trop Med Hyg. 2016 Dec 28;95(6 Suppl):62-71. doi: 10.4269/ajtmh.16-0180. Epub 2016 Jul 18.

34.

Global Epidemiology of Plasmodium vivax.

Howes RE, Battle KE, Mendis KN, Smith DL, Cibulskis RE, Baird JK, Hay SI.

Am J Trop Med Hyg. 2016 Dec 28;95(6 Suppl):15-34. doi: 10.4269/ajtmh.16-0141. Epub 2016 Jul 11. Review.

35.

The Community As the Patient in Malaria-Endemic Areas: Preempting Drug Resistance with Multiple First-Line Therapies.

Boni MF, White NJ, Baird JK.

PLoS Med. 2016 Mar 29;13(3):e1001984. doi: 10.1371/journal.pmed.1001984. eCollection 2016 Mar.

36.

Assessment of Point-of-Care Diagnostics for G6PD Deficiency in Malaria Endemic Rural Eastern Indonesia.

Satyagraha AW, Sadhewa A, Elvira R, Elyazar I, Feriandika D, Antonjaya U, Oyong D, Subekti D, Rozi IE, Domingo GJ, Harahap AR, Baird JK.

PLoS Negl Trop Dis. 2016 Feb 19;10(2):e0004457. doi: 10.1371/journal.pntd.0004457. eCollection 2016 Feb.

37.

Ion exchange at the critical point of solution.

Savoy JD, Baird JK, Lang JR.

J Chromatogr A. 2016 Mar 11;1437:58-66. doi: 10.1016/j.chroma.2016.01.029. Epub 2016 Jan 16.

PMID:
26884137
38.

Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.

Nelwan EJ, Ekawati LL, Tjahjono B, Setiabudy R, Sutanto I, Chand K, Ekasari T, Djoko D, Basri H, Taylor WR, Duparc S, Subekti D, Elyazar I, Noviyanti R, Sudoyo H, Baird JK.

BMC Med. 2015 Dec 11;13:294. doi: 10.1186/s12916-015-0535-9.

39.
40.

Optimum population-level use of artemisinin combination therapies: a modelling study.

Nguyen TD, Olliaro P, Dondorp AM, Baird JK, Lam HM, Farrar J, Thwaites GE, White NJ, Boni MF.

Lancet Glob Health. 2015 Dec;3(12):e758-66. doi: 10.1016/S2214-109X(15)00162-X. Epub 2015 Nov 4.

41.

The challenges of introducing routine G6PD testing into radical cure: a workshop report.

Ley B, Luter N, Espino FE, Devine A, Kalnoky M, Lubell Y, Thriemer K, Baird JK, Poirot E, Conan N, Kheong CC, Dysoley L, Khan WA, Dion-Berboso AG, Bancone G, Hwang J, Kumar R, Price RN, von Seidlein L, Domingo GJ.

Malar J. 2015 Sep 29;14:377. doi: 10.1186/s12936-015-0896-8.

42.

Global database of matched Plasmodium falciparum and P. vivax incidence and prevalence records from 1985-2013.

Battle KE, Guerra CA, Golding N, Duda KA, Cameron E, Howes RE, Elyazar IR, Baird JK, Reiner RC Jr, Gething PW, Smith DL, Hay SI.

Sci Data. 2015 Aug 18;2:150012. doi: 10.1038/sdata.2015.12. eCollection 2015.

43.

Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency.

Kheng S, Muth S, Taylor WR, Tops N, Kosal K, Sothea K, Souy P, Kim S, Char CM, Vanna C, Ly P, Ringwald P, Khieu V, Kerleguer A, Tor P, Baird JK, Bjorge S, Menard D, Christophel E.

BMC Med. 2015 Aug 25;13:203. doi: 10.1186/s12916-015-0441-1.

44.

Malaria eradication and elimination: views on how to translate a vision into reality.

Tanner M, Greenwood B, Whitty CJ, Ansah EK, Price RN, Dondorp AM, von Seidlein L, Baird JK, Beeson JG, Fowkes FJ, Hemingway J, Marsh K, Osier F.

BMC Med. 2015 Jul 25;13:167. doi: 10.1186/s12916-015-0384-6.

45.

Global extent of chloroquine-resistant Plasmodium vivax - Authors' reply.

Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ.

Lancet Infect Dis. 2015 Jun;15(6):630-1. doi: 10.1016/S1473-3099(15)00018-3. Epub 2015 May 17. No abstract available.

46.

Still defining optimal primaquine therapy against relapse after 63 years of continuous use.

Baird JK.

Travel Med Infect Dis. 2015 May-Jun;13(3):215-6. doi: 10.1016/j.tmaid.2015.04.006. Epub 2015 Apr 30. No abstract available.

PMID:
25971961
47.

Defining the relationship between Plasmodium vivax parasite rate and clinical disease.

Battle KE, Cameron E, Guerra CA, Golding N, Duda KA, Howes RE, Elyazar IR, Price RN, Baird JK, Reiner RC Jr, Smith DL, Gething PW, Hay SI.

Malar J. 2015 May 7;14:191. doi: 10.1186/s12936-015-0706-3.

48.

Large-volume protein crystal growth for neutron macromolecular crystallography.

Ng JD, Baird JK, Coates L, Garcia-Ruiz JM, Hodge TA, Huang S.

Acta Crystallogr F Struct Biol Commun. 2015 Apr;71(Pt 4):358-70. doi: 10.1107/S2053230X15005348. Epub 2015 Mar 30.

49.

G6PD deficiency at Sumba in Eastern Indonesia is prevalent, diverse and severe: implications for primaquine therapy against relapsing Vivax malaria.

Satyagraha AW, Sadhewa A, Baramuli V, Elvira R, Ridenour C, Elyazar I, Noviyanti R, Coutrier FN, Harahap AR, Baird JK.

PLoS Negl Trop Dis. 2015 Mar 6;9(3):e0003602. doi: 10.1371/journal.pntd.0003602. eCollection 2015 Mar.

50.

Severe morbidity and mortality risk from malaria in the United States, 1985-2011.

Hwang J, Cullen KA, Kachur SP, Arguin PM, Baird JK.

Open Forum Infect Dis. 2014 Jun 30;1(1):ofu034. doi: 10.1093/ofid/ofu034. eCollection 2014 Mar.

Supplemental Content

Loading ...
Support Center